Search results
Showing 136 to 150 of 181 results for nice conference
NICE has developed a medtech innovation briefing (MIB) on FLEXISEQ for osteoarthritis
Axxent electronic brachytherapy system for early stage breast cancer (MIB76)
NICE has developed a medtech innovation briefing (MIB) on Axxent electronic brachytherapy system for early stage breast cancer
The social care guidance manual
Show all sections
- 1 Introduction
- 2 The scope
- 3 The Guidance Development Group
- 4 Developing review questions and planning the systematic review
- 5 Identifying the evidence: literature searching and evidence submission
- 6 Reviewing the evidence
- 7 Incorporating economic evaluation
- 8 Linking social care guidance to other NICE guidance
NICE has developed a medtech innovation briefing (MIB) on the S-Cath System for suprapubic catheterisations
Reversal of the anticoagulant effect of dabigatran: idarucizumab (ESNM73)
Summary of the evidence on idarucizumab for reversing the anticoagulant effect of dabigtatran to inform local NHS planning and decision-making
Evidence-based recommendations on multiplex allergen testing, using ImmunoCAP ISAC 112 in people with allergy that is difficult to diagnose.
ClearWay RX for drug delivery to coronary artery thrombotic lesions (MIB55)
NICE has developed a medtech innovation briefing (MIB) on ClearWay RX for drug delivery to coronary artery thrombotic lesions
Improving awareness of Familial Hypercholesterolaemia in primary care
The Wales Familial Hypercholesterolaemia (FH) service, based around NICE CG71, aims to provide an equitable opportunity for the people...
Spectra Optia for automatic red blood cell exchange in people with sickle cell disease (MTG28)
Evidence-based recommendations on Spectra Optia for automated red blood cell exchange in people with sickle cell disease.
This quality standard covers services for domestic violence and abuse in adults and young people (aged 16 and over). It includes identifying and supporting people experiencing domestic violence or abuse, as well as support for those who carry it out. It also covers children and young people (under 16) who are affected by domestic violence or abuse that is not carried out against them. It describes high-quality care in priority areas for improvement.
View quality statements for QS116Show all sections
Sections for QS116
- Introduction
- List of quality statements
- Quality statement 1: Asking about domestic violence and abuse
- Quality statement 2: Response to domestic violence and abuse
- Quality statement 3: Referral to specialist support services for people experiencing domestic violence or abuse
- Quality statement 4: Referral to specialist services for people perpetrating domestic violence or abuse
- Using the quality standard
- Diversity, equality and language
Xpert Carba-R to identify people carrying carbapenemase-producing organisms (MIB52)
NICE has developed a medtech innovation briefing (MIB) on the Xpert Carba-R to identify people carrying carbapenemase-producing organisms
NICE has developed a medtech innovation briefing (MIB) on MiniMed 640G system with SmartGuard for managing blood glucose levels in people with type 1 diabetes
Interventional procedures programme manual
EarlySense for heart and respiratory monitoring and predicting patient deterioration (MIB49)
NICE has developed a medtech innovation briefing (MIB) on EarlySense for heart and respiratory monitoring and predicting patient deterioration
C3 glomerulopathy in the native kidney: eculizumab (ESUOM49)
Summary of the evidence on eculizumab for treating C3 glomerulopathy in the native kidney inform local NHS planning and decision-making